Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644043 | 0.87 | GCGR (0.50) | GCGRALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL2643785 | 0.87 | GCGR (0.55) | GCGRALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL2646338 | 0.80 | GCGR (0.53) | GCGRALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL2644201 | 0.78 | APOBEC3G (0.54) | GCGRALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL2645160 | 0.76 | ALDH1A1 (0.58) | GCGRALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL2644435 | 0.73 | GCGR (0.69) | GCGRALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL2644114 | 0.73 | GCGR (0.59) | GCGRALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL2644076 | 0.70 | GCGR (0.53) | GCGRALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL2645219 | 0.69 | HPGD (0.60) | GCGRALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL2644096 | 0.67 | APOBEC3G (0.67) | GCGRALDH1A1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097557-A1 | Cyanothiophene derivatives, compositions containing such compounds and methods of use | DUFFY JOSEPH L (US) | 2004-05-20 | — | — | US | claimed |
| US-20040097557-A1 | Cyanothiophene derivatives, compositions containing such compounds and methods of use | DUFFY JOSEPH L (US) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097557-A1 | Cyanothiophene derivatives, compositions containing such compounds and methods of use | GLP1R, GPR119, GCGR | GCGR 3/4885ALDH1A1 2652/4885LMNA 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.